Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gains from Investment Securities: 2010-2021

Historic Gains from Investment Securities for Neurocrine Biosciences (NBIX) over the last 9 years, with Dec 2021 value amounting to $1.8 million.

  • Neurocrine Biosciences' Gains from Investment Securities fell 85.94% to $1.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $36.2 million, marking a year-over-year decrease of 59.62%. This contributed to the annual value of $271.6 million for FY2024, which is 35.26% up from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Gains from Investment Securities is $1.8 million, which was down 67.86% from $5.6 million recorded in Q2 2021.
  • Neurocrine Biosciences' Gains from Investment Securities' 5-year high stood at $76.6 million during Q4 2019, with a 5-year trough of $100,000 in Q3 2019.
  • In the last 3 years, Neurocrine Biosciences' Gains from Investment Securities had a median value of $9.2 million in 2020 and averaged $18.8 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Gains from Investment Securities crashed by 90.34% in 2018 and then spiked by 1,233.10% in 2019.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Gains from Investment Securities stood at $59.5 million in 2017, then tumbled by 90.34% to $5.7 million in 2018, then surged by 1,233.10% to $76.6 million in 2019, then tumbled by 83.29% to $12.8 million in 2020, then tumbled by 85.94% to $1.8 million in 2021.
  • Its last three reported values are $1.8 million in Q4 2021, $5.6 million for Q2 2021, and $16.0 million during Q1 2021.